(Q34217281)

31 July 2017

title

Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study (English)

1 reference

31 July 2017

1 reference

1 reference

1 reference

Carmela Calandra

1

1 reference

31 July 2017

Rina Giuseppa Russo

series ordinal

2

1 reference

31 July 2017

Maria Luca

series ordinal

3

1 reference

31 July 2017

publication date

1 June 2012

1 reference

31 July 2017

published in

Psychiatric Quarterly

1 reference

31 July 2017

volume

83

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

177-185

1 reference

Comorbidity and age of onset of eating disorders in gay men, lesbians, and bisexuals

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Binge eating disorder treatment: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Pharmacologic treatment of binge eating disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

A double-blind, placebo-controlled trial of fluvoxamine in binge eating disorder: a high placebo response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Placebo-controlled trial of sertraline in the treatment of binge eating disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

A 12 to 24 weeks pilot study of sertraline treatment in obese women binge eaters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

On the validity of the Beck Depression Inventory. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Utility and validity of the STAI with anxiety disorder patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Catecholamine reuptake inhibition causes weight loss by increasing locomotor activity and thermogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Investigation of the serotonin transporter regulatory region polymorphism in bulimia nervosa: relationships to harm avoidance, nutritional parameters, and psychiatric comorbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

The 5HTTLPR polymorphism, psychopathologic symptoms, and platelet [3H-] paroxetine binding in bulimic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11126-011-9192-0

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

12 December 2020

A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder.

1 reference

12 December 2020

Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial.

1 reference

12 December 2020

Comparison of binge eating disorder and bulimia nervosa in a community sample

1 reference

12 December 2020

Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression

1 reference

12 December 2020

Body image evaluations in obese females with binge eating disorder

1 reference

12 December 2020

The Arizona Sexual Experience Scale (ASEX): reliability and validity

1 reference

12 December 2020

Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials

1 reference

12 December 2020

Binge eating disorder: a stable syndrome.

1 reference

12 December 2020

Gender differences in outcome of eating disorders: A retrospective cohort study

1 reference

12 December 2020

Antidepressant treatment of binge-eating disorder: research findings and clinical guidelines.

1 reference

12 December 2020

Long-term side effects of SSRIs: sexual dysfunction and weight gain.

1 reference

12 December 2020

Treatment of patients with eating disorders,third edition. American Psychiatric Association.

1 reference

12 December 2020

10.1007/S11126-011-9192-0

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1047216342

0 references

1 reference